

Amendments to the Claims:

Please cancel claims 1-9 without prejudice. Please add new claims 10-29 as shown below in the list of Claims.

List of Claims:

Claim 1-9 (canceled).

Claim 10 (new). A method for determining the clinical malignancy of familial amyotrophic lateral sclerosis (FALS), comprising isolating mutant superoxide dismutase (SOD1) from a FALS patient and evaluating the binding of said mutant SOD1 to one or more factors selected from the group consisting of: TRAP δ ; NEDL1; Dvl1; and a complex between NEDL1 and TRAP δ .

Claim 11 (new). The method of claim 10, wherein said mutant SOD1 is isolated from the neurons of said FALS patient.

Claim 12 (new). The method of claim 10 wherein said one or more factors include TRAP δ .

Claim 13 (new). The method of claim 10, wherein said one or more factors includes NEDL1.

Claim 14 (new). The method of claim 10, wherein said one or more factors includes Dvl1.

Claim 15 (new). The method of claim 10, wherein said one or more factors includes a complex between NEDL1 and TRAP δ .

Claim 16 (new). A method for determining if a test compound is useful in the treatment of FALS comprising:

a) measuring the binding of a mutant SOD1 to one or more factors selected from the group consisting of TRAP δ , NEDL1, Dvl1, and a complex between NEDL1 and TRAP δ , wherein said binding is evaluated in the presence of said test compound;

b) measuring the binding of a mutant SOD1 to one or more factors selected from the group consisting of TRAP δ , NEDL1, Dvl1, and a complex between NEDL1 and TRAP δ , wherein said binding is evaluated in the absence of said test compound;

c) comparing the results of the binding measurement of step a) with the results of step b) to determine whether said test compound is an inhibitor of binding.

Claim 17 (new). The method of claim 16, wherein said mutant SOD1 is isolated from a patient with FALS.

Claim 18 (new). The method of claim 17, wherein said mutant SOD1 is isolated from the neurons of said patient.

Claim 19 (new). The method of claim 16, wherein said one or more factors includes TRAP δ .

Claim 20 (new). The method of claim 16, wherein said one or more factors includes NEDL1.

Claim 21 (new). The method of claim 16, wherein said one or more factors includes Dvl1.

Claim 22 (new). The method of claim 16, wherein said one or more factors includes a complex between TRAP δ and NEDL1.

Claim 23 (new). A method of treating a patient for FALS, comprising administering to said patient an effective amount of a compound that inhibits the binding of mutant SOD1 to one or more factors selected from the group consisting of TRAP δ , NEDL1 and Dvl1.

Claim 24 (new). The method of claim 23, wherein said mutant SOD1 is isolated from a patient with FALS.

Claim 25 (new). The method of claim 23, wherein said mutant SOD1 is isolated from the neurons of said patient.

Claim 26 (new). The method of claim 23, wherein said one or more factors includes TRAP δ .

Claim 27 (new). The method of claim 23, wherein said one or more factors includes NEDL1.

Claim 28 (new). The method of claim 23, wherein said one or more factors includes Dvl1.

Claim 29 (new). The method of claim 23, wherein said one or more factors includes a complex between TRAP δ and NEDL1.